All articles tagged with #kodiak sciences
Kodiak Sciences shares jumped nearly 178% to $89.92, while MongoDB fell 18.5% and Boeing dropped 6.9%. Nvidia and Roblox also saw significant midday moves, reflecting a volatile session for tech and industrial names.
Kodiak Sciences stock jumped 178% after its two eye drugs, Zenkuda and tabirafusp-ted, matched Regeneron’s Eylea in a Phase 3 trial for wet age-related macular degeneration. Zenkuda allowed over half of patients to receive injections only once every six months, compared to every eight weeks for Eylea. The company plans to file for FDA approval of Zenkuda in the fourth quarter of 2026.
Kodiak Sciences shares jumped 128% after its Phase 3 DAYBREAK trial showed its drug Zenkuda matched the efficacy of aflibercept for wet age-related macular degeneration. The company plans to file for FDA approval in Q4 2026.
Kodiak Sciences Inc has decided to discontinue the development of its experimental drug, tarcocimab tedromer, for the treatment of diabetic macular edema. The decision was made after the drug failed to meet its main goal in two late-stage studies and was found to cause an increase in cataracts over time in patients. As a result, the company's shares tumbled 40% in premarket trading.